title: The role of secondary cytoreduction in the treatment of ovarian cancer: Hacettepe University experience.
abstract: OBJECTIVE
  This study was undertaken to evaluate the role of secondary cytoreduction in patients with recurrent epithelial ovarian cancer.
  
  
  METHODS
  Secondarily, cytoreduced patients were retrospectively analyzed with respect to the clinicopathologic variables.
  
  
  RESULTS
  A total of 64 patients were evaluated in this report. Multivariable analysis revealed 3 factors to be significant: optimal cytoreduction during primary (P = .003, odds ratio [OR]: 0.30; 95% CI: 0.14-0.66), secondary cytoreduction (P = .04, OR: 0.47; 95% CI: 0.22-0.99), and the endometrioid histologic type (P = .005, OR: 0.09; 95% CI: 0.02-0.48). Intrinsic factors of the tumors (grade, stage, age), size, and number of recurrent tumors were nonsignificant.
  
  
  CONCLUSIONS
  Secondary cytoreductive surgery should be offered in selected recurrent epithelial ovarian cancer patients. Further prospective randomized series are needed to determine specific recommendations.
authors.affiliation: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Hacettepe University Faculty of Medicine, Sihhiye, Ankara, Turkey.
authors.forename: Ali
authors.initials: A
authors.lastname: Ayhan
authors.forename: Murat
authors.initials: M
authors.lastname: Gultekin
authors.forename: Cagatay
authors.initials: C
authors.lastname: Taskiran
authors.forename: Guldeniz
authors.initials: G
authors.lastname: Aksan
authors.forename: Nilufer Yigit
authors.initials: NY
authors.lastname: Celik
authors.forename: Polat
authors.initials: P
authors.lastname: Dursun
authors.forename: M Coskun
authors.initials: MC
authors.lastname: Salman
authors.forename: Kunter
authors.initials: K
authors.lastname: Yuce
authors.forename: Turkan
authors.initials: T
authors.lastname: Kucukali
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002277:Carcinoma / Q000473:pathology / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*; D011182:Postoperative Care; D011300:Preoperative Care; D018714:Radiotherapy, Adjuvant; D012086:Reoperation; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents